LIGAND PHARMACEUTICALS INC
LGNDUS売上高
$268M
百万USD
営業利益
$41M
百万USD
純利益
$124M
百万USD
ROE
12.2%
最新FY
EPS
$6.13
USD / 株
配当
$2.50
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $18M | $1.05 |
| FY2021 | Q2 | - | $31M | $1.79 |
| FY2021 | Q3 | - | $14M | $0.80 |
| FY2021 | FY | $277M | $57M | $3.31 |
| FY2022 | Q1 | $46M | $-15M | $-0.91 |
| FY2022 | Q2 | $57M | $-1M | $-0.05 |
| FY2022 | Q3 | $66M | $0M | $0.02 |
| FY2022 | FY | $196M | $-33M | $-1.98 |
| FY2023 | Q1 | $44M | $42M | $2.33 |
| FY2023 | Q2 | $26M | $2M | $0.13 |
| FY2023 | Q3 | $33M | $-10M | $-0.59 |
| FY2023 | FY | $131M | $52M | $2.94 |
| FY2024 | Q1 | $31M | $86M | $4.75 |
| FY2024 | Q2 | $42M | $-52M | $-2.88 |
| FY2024 | Q3 | $52M | $-7M | $-0.39 |
| FY2024 | FY | $167M | $-4M | $-0.22 |
| FY2025 | Q1 | $45M | $-42M | $-2.21 |
| FY2025 | Q2 | $48M | $5M | $0.24 |
| FY2025 | Q3 | $115M | $117M | $5.68 |
| FY2025 | FY | $268M | $124M | $6.13 |
| FY2026 | Q1 | $52M | $-13M | $-0.67 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $251M | $120M | $186M | $277M | $196M | $131M | $167M | $268M |
| 営業利益 | $44M | $68M | $164M | $807M | $26M | $79M | $3M | $12M | $-23M | $41M |
| 純利益 | $-2M | $13M | $143M | $629M | $-3M | $57M | $-33M | $52M | $-4M | $124M |
| 総資産 | $602M | $671M | $1.3B | $1.5B | $1.4B | $1.3B | $763M | $787M | $942M | $1.6B |
| 純資産 | $341M | $400M | $561M | $767M | $710M | - | - | - | - | - |
| 自己資本 | $341M | $400M | $561M | $767M | $710M | $821M | $597M | $701M | $830M | $1.0B |
| 営業CF | $63M | $94M | $194M | $-29M | $55M | $79M | $138M | $50M | $97M | $49M |
| EPS | $-0.08 | $0.53 | $5.96 | $31.85 | $-0.18 | $3.31 | $-1.98 | $2.94 | $-0.22 | $6.13 |
| BPS | $16.31 | $18.85 | $27.43 | $46.48 | $42.71 | $48.73 | $34.99 | $39.59 | $43.13 | $51.01 |
| ROE | -0.5% | 3.1% | 25.6% | 82.0% | -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% |